Results 101 to 110 of about 4,200 (201)

P-67: Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor [PDF]

, 2017
Aliskiren (SPP 100), an orally active renin inhibitor, has been shown to inhibit the production of angiotensin I and angiotensin II in healthy volunteers.
Mann, Jessica, Jensen, Chris, Stanton, Alice, O'Brien, Eoin, Barton, John, Bobillier, Bobillier   +5 more
core  

Aliskiren –An overview

Bangladesh Journal of Medicine, 2015
The renin-angiotensin system (RAS) or the renin-angiotensin-aldosterone system (RAAS) is a major endocrine/ paracrine system that regulates blood pressure (BP) via angiotensin release as well as fluid and electrolyte homeostasis via aldosterone release.
openaire   +2 more sources

Effects of Aliskiren on transdifferentiation induced by TGF-β₁ in human renal tubular epithelial cells

Linchuang shenzangbing zazhi, 2018
Objective To explore Aliskiren on transdifferentiation of renal tubular epithelial cells（ H KC） induced by TGF-β1 and to evaluate its effect on platelet derived growth factor（ PDGF-BB） 、vascular endothelialgrowth factor（ VEGF） expressing change. M ethods
HUANG Jian, CHEN Song, YANG Jing, MIN Ya-li   +3 more
doaj  

Renin inhibitors are a new direction in the treatment of arterial hypertension

Терапевтический архив, 2010
The paper covers current problems in the treatment of arterial hypertension. Renin is an important and promising therapeutic target. The direct renin inhibitor aliskiren (Rasilez) is a promising current effective antihypertensive agent that has cardio ...
Yuriy Aleksandrovich Vasyuk, Irina Akhmedkhanovna Sadulaeva, Elena Nikolaevna Yushchuk, Ol'ga Sergeevna Trofimenko, Mikhail Vasil'evich Chirkov, Viktoriya Sergeevna Fedoseeva, Kirill Georgievich Kulikov, Yu A Vasyuk, I A Sadulayeva, E N Yushchuk, O S Trofimenko, M V Chirkov, V S Fedoseyeva, K G Kulikov   +13 more
doaj  

Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication

, 2009
We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition
Parving, Hans-Henrik, Lewis, Edmund J, Lewis, Julia B, Hollenberg, Norman K, Persson, Frederik   +4 more
core   +1 more source

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

, 2011
We describe a mechanistic investigation of drug–drug interaction between aliskiren and grapefruit juice in healthy subjects. Twenty-eight subjects received an oral dose of aliskiren 300 mg (highest recommended clinical dose) with 300 mL water or ...
Zhao, Sally, Hariry, Sam, Alexander, Natalya, Hanna, Imad, Rebello, Sam, Jarugula, Venkateswar, Vapurcuyan, Arpine, Dahlke, Marion   +7 more
core  

Acquired Angioedema-A Challenge in Medical Practice: A Narrative Review. [PDF]

J Clin Med
Poznańska-Kurowska K, Skibińska M, Lorenz D, Aman Ur Rahman W, Kurowski M.   +4 more
europepmc   +1 more source

Effects of Amino Acid Point Mutations on the Local Hydrophobicity, Structural Stability, and Conformational Flexibility of P-Glycoprotein. [PDF]

Biomolecules
Năstasie AI, Isvoran A.
europepmc   +1 more source

Progress in research on RAAS inhibitors regulating inflammatory responses and oxidative stress: from molecular mechanisms to clinical evidence. [PDF]

Front Pharmacol
Yin H, Yang M, Zhang S, Li Q, Zhen D, Tang X.   +5 more
europepmc   +1 more source

Direct Renin Inhibition With Aliskiren Compared to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension: A Systematic Review. [PDF]

Cureus
Gapizov A, Mohammad A, Singla S, Singla B, Kumawat S, Ajay, Ali Z.   +6 more
europepmc   +1 more source